Authors: Emelly Rusli, MPH1, Aaron Galaznik, MD MBA1, Nicholas C. Coombs, PhD, MSTAT2, Emily R. Beamon, PhD, MA, MP2, and Tanya Wildes MD, MSCI3
1 Carevive Systems, Inc.
2 Piedmont Research Strategies
3 University of Nebraska Medical Center
Electronic patient-reported outcomes (ePRO) for symptom monitoring in oncology practice improves survival, accelerates time to therapy, and manages resource utilization. As many patients with myeloma are treated with oral medications, with fewer clinic visits, ePROs present an opportunity to fill unmet needs for symptom monitoring for multiple myeloma (MM) patients. This study aims to describe the severe symptom trajectory in MM population who utilized remote symptom monitoring with ePRO.
- Eligible MM patients who participated in the Carevive PROmPT® remote symptom monitoring from March 1, 2021, to October 30, 2022, were enrolled.
- Patients received baseline and weekly surveys assessing symptom burden, function, and overall health impact.
- Index date was defined as the date of baseline questionnaire completion.
- Patients were followed for 16 weeks, until loss of follow-up, termination by study sponsor, or death, whichever came earliest.
- Measures of symptoms were derived from the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and were reported during active patient-weeks, defined as the time period (in weeks) when each patient completed the survey.
- A total of 49 patients were included.
- Average age was 68.6 (SD=1.2) years, 37% were female, and 22% were frail at baseline by IMWG criteria (Table 1).
- Median survey follow-up was 13 weeks; survey completion rate was 85%.
- Median time to first reported severe symptom was 2 weeks.
- Almost half (45%) reported at least one severe symptom during study period, with 14% of patients reported at Week 1 and highest proportion of patients (21%) reported at Week 4 (Figure 1).
- The prevalence of severe symptoms ranged between 6-21% across active patient-weeks (Figure 1) compared to 41-68% for moderate and 17-50% for mild symptoms, respectively (Figure 2).
- Fatigue (22%) and general pain (21%) were the most prevalent severe symptoms across all active patient-weeks (Figure 3).
This study demonstrates the value of ePRO for symptom monitoring, an unmet need in MM population. Overall high survey completion rate suggests patients’ compliance and value perception towards communicating symptoms and wellbeing to clinicians in real-time.